Antioxidant properties of calcium antagonists related to membrane biophysical interactions

American Journal of Cardiology

Volumn 84, Issue 4 SUPPL. 1, 1999, Pages 16-22

  Mason, R Preston ^a   Mak, I Tong ^b   Trumbore, Mark W ^c   Mason, Pamela E ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CALCIUM ANTAGONIST; ANTIOXIDANT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; VERAPAMIL; AMLODIPINE BESYLATE; CALCIUM CHANNEL; MALONALDEHYDE; PHOSPHOLIPID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIOXIDANT ACTIVITY; ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; ENTHALPY; HEART PROTECTION; LIPID PEROXIDATION; MALE; MICROSOME MEMBRANE; NONHUMAN; PRIORITY JOURNAL; RAT; X RAY DIFFRACTION; ANIMAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; INTRACELLULAR MEMBRANE; LIVER MICROSOME; METABOLISM; RADIOASSAY; SPRAGUE DAWLEY RAT; CARDIOVASCULAR EFFECT; CELL PROTECTION; CONFERENCE PAPER; CONTROLLED STUDY; MOUSE;

AMLODIPINE; ANIMALS; ANTIOXIDANTS; CALCIUM CHANNEL BLOCKERS; CALORIMETRY, DIFFERENTIAL SCANNING; DILTIAZEM; DOSE-RESPONSE RELATIONSHIP, DRUG; INTRACELLULAR MEMBRANES; LIPID PEROXIDATION; MALE; MICROSOMES, LIVER; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; VERAPAMIL; X-RAY DIFFRACTION;

EID: 0033584292     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00360-4     Document Type: Article

References (24)

1. Janis R.A., Silver P.J., Triggle D.J. Drug action and calcium regulation. Adv Drug Res. 16:1987;309-591.
2. Janero D.R., Burghardt B., Lopez R. Protection of cardiac membrane phospholipid against oxidative injury by calcium antagonists. Biochem Pharmacol. 37:1988;4197-4203.
3. Ondrias K., Misik V., Gergel D., Stasko A. Lipid peroxidation of phosphatidylcholine liposomes depressed by the calcium channel blockers nifedipine and verapamil and by the antiarrhythmic-antihypoxic drug stobadine. Biochim Biophys Acta. 1003:1989;238-245.
4. Mak I.T., Weglicki W.B. Comparative antioxidant activities of propranolol, nifedipine, verapamil, and diltiazem against sarcolemmal membrane lipid peroxidation. Circ Res. 66:1990;1449-1452.
5. Mak I.T., Kramer J.H., Weglicki W.B. Antioxidant properties of active and inactive isomers of nicardipine in cardiac membranes, endothelial cells, and perfused rat hearts. Coron Artery Dis. 3:1992;1095-1103.
6. Ross R. The pathogenesis of atherosclerosis a perspective for the 1990s . Nature. 362:1986;801-809.
7. Lichtlen P.R., Hugenholtz P.G., Rafflenbeul W., Hecker H., Jost S., Nikutta P., Deckers J.W. Retardation of coronary artery disease in humans by the calcium-channel blocker nifedipine results of the INTACT study (International Trial on Antiatherosclerotic Therapy) . Cardiovasc Drugs Ther. 4:1990;S1047-S1068.
8. Keogh A.M., Schroeder J.S. A review of calcium antagonists and atherosclerosis. J Cardiovasc Pharmacol. 16:1990;S28-S35.
9. Henry PD. Antiperoxidative actions of calcium antagonists and atherogenesis. J Cardiovasc Pharmacol 1991;18:S6-S10.
10. Steinberg D. Antioxidants and atherosclerosis a current assessment . Circulation. 84:1991;1420-1425.
11. Janero D.R., Burghardt B. Antiperoxidant effects of dihydropyridine calcium antagonists. Biochem Pharmacol. 38:1989;4344-4348.
12. Mak I.T., Boehme P., Weglicki W.B. Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells correlation of protection with preservation of glutathione levels . Circ Res. 70:1992;1099-1103.
13. Mason R.P., Campbell S., Wang S., Herbette L.G. Comparison of location and binding for the positively charged 1,4-dihydropyridine calcium channel antagonist amlodipine with uncharged drugs of this class in cardiac membranes. Mol Pharmacol. 36:1989;634-640.
14. 2+ channel blockers to the membrane lipid bilayer. Mol Pharmacol. 41:1992;315-321.
15. May H.E., McCay P.B. Reduced triphosphopyridine nucleotide oxidase-catalyzed alterations of membrane phospholipids. J Biol Chem. 243:1968;2296-2305.
16. Mak I.T., Misra H.P., Weglicki W.B. Temporal relationship of free radical-induced lipid peroxidation and loss of latent enzyme activity in highly enriched hepatic lysosomes. J Biol Chem. 258:1983;13733-13737.
17. Bangham A.D., Standish M.M., Watkins J.C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 13:1965;238-252.
18. 2+ and the phospholipid bilayer within isolated sarcoplasmic reticulum. Biophys J. 20:1985;245-272.
19. Moody M.F. X-ray diffraction pattern of nerve myelin a method for determining the phases . Science. 142:1963;1173-1174.
20. Jain M.K., Wu N.M. Effect of small molecules on the dipalmitoyl lecithin liposomal bilayer. J Membr Biol. 34:1977;157-201.
21. Bauerle H.-D., Seelig J. Interaction of charged and uncharged calcium channel antagonists with phospholipid membranes binding equilibrium, binding enthalpy, and membrane location . Biochem J. 30:1991;7203-7211.
22. Packer M., O'Connor C.M., Ghali J.K., Pressler M.L., Carson P.E., Belkin R.N., Miller A.B., Neuberg G.W., Frid D., Wertheimer J.H., Cropp A.B., DeMets D.L. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 335:1996;1107-1114.
23. Byington R.P., Chen J., Furberg C.D., Pitt B. Effect of amlodipine on cardiovascular events and procedures. J Am Coll Cardiol. 33:1999;314A. (Abstr.).
24. Mason R.P., Walter M.F., Trumbore M.W., Olmstead E.G. Jr, Mason P.E. Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol. 31:1999;275-281.